HUTCHMED (China) Limited (GB:HCM) has released an update.
HUTCHMED (China) Limited announced that its partner Takeda received a positive opinion from the European Medicines Agency’s CHMP for the approval of fruquintinib, a treatment for metastatic colorectal cancer. This marks a significant step toward providing a novel oral therapy option for patients in the EU, with potential marketing authorization expected to follow. Fruquintinib has shown promising results in the FRESCO-2 Phase III trial, offering a potential new standard of care for this patient group.
For further insights into GB:HCM stock, check out TipRanks’ Stock Analysis page.
